United States v. Johnson

Court of Appeals for the First Circuit·Decided May 28, 2026·No. 24-1583·Published

Opinion

United States Court of Appeals For the First Circuit

No. 24-1583 UNITED STATES OF AMERICA, Appellee,

v.

ADAM JOHNSON,

Defendant, Appellant.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MAINE

[Hon. Lance E. Walker, U.S. District Judge]

Before

Montecalvo, Kayatta, and Rikelman, Circuit Judges.

Ronald W. Bourget for appellant.

Brian S. Kleinbord, Assistant U.S. Attorney, with whom Craig M. Wolff, Acting U.S. Attorney, was on brief, for appellee.

May 28, 2026

KAYATTA, Circuit Judge. A jury convicted Adam Johnson of conspiracy to distribute and to possess with intent to distribute 400 grams or more of fentanyl in violation of 21 U.S.C. §§ 846, 841(a)(1), and 841(b)(1)(A). On appeal, Johnson contends that the proceedings below were tainted by the court's failure to hold an evidentiary hearing before denying his motions to exclude his plea and cooperation agreements as well as his grand jury testimony. Johnson also challenges his sentence, asserting that the court erred in enhancing his offense level based on testimony of a deceased witness and in refusing to grant him credit for acceptance of responsibility despite his prior cooperation.

Finding Johnson's arguments either unpreserved or lacking merit, we affirm the verdict and sentence. Our reasoning follows.

I.

This case presents an unusual procedural history spanning over half a decade, five different defense attorneys, and two district court dockets.

On February 21, 2018, New Hampshire State Police stopped Johnson for a defective taillight and found fifty-three grams of heroin on his person. Johnson confessed to purchasing drugs and provided information regarding several distributors, after which he was extradited to Maine on a warrant for a failure to appear in a separate matter. Upon his return to Maine, Johnson enrolled as

a confidential source (CS) for the Drug Enforcement Agency (DEA). He entered into two agreements with the DEA, beginning on May 31, 2018. 1 The DEA anticipated that, in exchange for his cooperation -- which included providing real-time information to agents and disclosing information about his suppliers -- Johnson would not be charged with possessing heroin at the time of his February arrest.

But Johnson's work as a CS did not itself entitle him to immunity from any and all criminal charges. Around January 3, 2019, the government served Johnson with a target letter stating that they had received "substantial evidence relating to [his] violation of federal narcotics trafficking laws." Johnson received his first appointed counsel at that point. Although he had been terminated as a CS for the DEA, Johnson continued to cooperate with the government through proffers to government agents on March 27, 2019, and again on October 29, 2019.2 In the

1 The first agreement pertained to work as a CS from May 31, 2018, through September 1, 2018. The second agreement pertained to work as a CS from September 1, 2018, through December 1, 2018. The DEA deactivated Johnson as a CS on November 29, 2018, due to his incarceration.

2 Johnson signed a "proffer" agreement on March 27, 2019, which provided that "[i]n any prosecution brought" against him, "the Government will not offer in evidence in its case-inchief . . . any statements made by [Johnson] at the meeting, except in a prosecution for false statements, obstruction of justice or perjury with respect to any acts committed or statements made during or after the meeting or testimony given after the meeting."

intervening months, Johnson's first counsel withdrew due to a conflict of interest. During the October proffer, the government provided to Johnson and his new appointed counsel an overview of the proposed plea and cooperation agreements. At some point, Johnson agreed to testify before a grand jury to assist the government in its prosecution of other drug distributors.

On December 11, 2019, minutes prior to testifying before the grand jury, Johnson signed the cooperation and plea agreements. The plea agreement contained a provision stating that, in the event of a breach by Johnson, "[t]he United States may use any statement that [Johnson] made pursuant to this Agreement, including statements made during plea discussions and plea colloquies, and the fact that [Johnson] pleaded guilty." Additionally, Johnson agreed to "waive[] any claim under Rule 410 of the Federal Rules of Evidence or Rule 11(f) of the Federal Rules of Criminal Procedure that such statements and guilty plea are inadmissible" in the event of such breach.

The cooperation agreement also contained a provision titled "Consequences of Breach," which provided that, if Johnson "violates or fails to perform any obligations under this Agreement or under the plea agreement ('a breach'), the United States will be released from its obligations hereunder and may fully prosecute [Johnson]." As most relevant to this appeal, under Section A of the breach provision, Johnson agreed that the government could

"use any statement that [he] made pursuant to [the] Agreement, including statements made during proffers, debriefings, [and] grand jury sessions" in the event of breach. He further "waive[d] any claim under Rule 410 of the Federal Rules of Evidence or Rule 11(f) of the Federal Rules of Criminal Procedure that such statements and guilty plea are inadmissible."

When Johnson signed the final written agreements just before testifying to the grand jury, his appointed counsel was not present. Rather, he was represented by "fill-in" counsel arranged by his attorney. There is no claim, however, that either written agreement differed in relevant substance from what was discussed at the October meeting between Johnson, his appointed counsel, and the government. In his testimony before the grand jury, Johnson confirmed both that he had had enough time to discuss the agreements with the substitute attorney and that he was comfortable proceeding with the substitute attorney. Johnson further admitted to distributing fentanyl and heroin to support his addiction, and he named his supplier and other distributors. When asked if he hoped to receive a lower sentence for his cooperation, Johnson responded, "Yes."

The following month, on January 29, 2020, the government filed an information charging Johnson with conspiracy to distribute and to possess with intent to distribute 400 grams or more of fentanyl in violation of 21 U.S.C. §§ 846, 841(a)(1), and

841(b)(1)(A). Johnson was first scheduled to plead guilty to this information on February 12, 2020 -- the same date of his arraignment on the information and his waiver of indictment. That hearing was initially rescheduled for unknown reasons to February 28 and then to March 25, 2020. On March 19, 2020, the court again rescheduled Johnson's hearing to May 13, 2020, in accordance with the COVID-19 pandemic general orders. On April 20, 2020, Johnson's appointed counsel filed a motion to withdraw from his case. The court granted that motion and cancelled the May 13 hearing via minute order, stating it would reschedule the hearing when "the Court resume[d] in-court appearances." On October 8, 2020, Johnson's new attorney -- his third to that point -- filed a motion requesting his plea hearing be continued. After several more continuances, on August 24, 2021, the plea hearing was cancelled. A few weeks later, Johnson's attorney filed a motion to withdraw from his case. The district court made its grant of the motion "contingent upon [Johnson] submitting a new financial affidavit and it being approved by the Court." Neither Johnson nor his attorney submitted a new financial affidavit.

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Johnson, (1st Cir. 2026).

United States v. Johnson (United States v. Johnson) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Brady v. Maryland
373 U.S. 83 (Supreme Court, 1963)
Weatherford v. Bursey
429 U.S. 545 (Supreme Court, 1977)
United States v. Ruiz
536 U.S. 622 (Supreme Court, 2002)
Puckett v. United States
556 U.S. 129 (Supreme Court, 2009)
United States v. Brown
621 F.3d 48 (First Circuit, 2010)
United States v. Graciani
61 F.3d 70 (First Circuit, 1995)
United States v. Hines
196 F.3d 270 (First Circuit, 1999)
United States v. Cyr
337 F.3d 96 (First Circuit, 2003)
United States v. Newbert
504 F.3d 180 (First Circuit, 2007)
United States v. Deppe
509 F.3d 54 (First Circuit, 2007)
United States v. Garrasteguy
559 F.3d 34 (First Circuit, 2009)
United States v. Ilario M.A. Zannino
895 F.2d 1 (First Circuit, 1990)
United States v. William W. Lilly
983 F.2d 300 (First Circuit, 1992)
United States v. Josee Antonio Nunez-Rodriguez
92 F.3d 14 (First Circuit, 1996)
Brown v. Plata
131 S. Ct. 1910 (Supreme Court, 2011)
United States v. Cox
851 F.3d 113 (First Circuit, 2017)
United States v. Lee
892 F.3d 488 (First Circuit, 2018)